TECENTRIQ™ (atezolizumab) is NOW FDA APPROVED for the treatment of patients with locally advanced or metastatic urothelial carcinoma who:

- Have disease progression during or following platinum-containing chemotherapy
- Have disease progression within 12 months of neoadjuvant or adjuvant treatment with platinum-containing chemotherapy

This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

To learn more, please visit www.TECENTRIQ.com

### Codes for Your Reference

<table>
<thead>
<tr>
<th>Type</th>
<th>Code</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>NDC</td>
<td>50242-917-01 50242-0917-01</td>
<td>Carton containing one 1200 mg/20 mL single-dose vial</td>
</tr>
</tbody>
</table>

### ICD-10-CM

#### Upper Tract Urothelial

- C65.1 Malignant neoplasm of the right renal pelvis
- C65.2 Malignant neoplasm of the left renal pelvis
- C65.9 Malignant neoplasm of the unspecified renal pelvis
- C66.1 Malignant neoplasm of the right ureter
- C66.2 Malignant neoplasm of the left ureter
- C66.9 Malignant neoplasm of the unspecified ureter

#### Lower Tract Urothelial

- C67.0 Malignant neoplasm of trigone of bladder
- C67.1 Malignant neoplasm of dome of bladder
- C67.2 Malignant neoplasm of lateral wall of bladder
- C67.3 Malignant neoplasm of anterior wall of bladder
- C67.4 Malignant neoplasm of posterior wall of bladder
- C67.5 Malignant neoplasm of bladder neck
- C67.6 Malignant neoplasm of ureteric orifice
- C67.7 Malignant neoplasm of urachus
- C67.8 Malignant neoplasm of overlapping sites of bladder
- C67.9 Malignant neoplasm of bladder, unspecified
- C68.0 Malignant neoplasm of the urethra

**IMPORTANT SAFETY INFORMATION**

Serious and sometimes fatal adverse reactions occurred with TECENTRIQ treatment. Warnings and precautions include immune-related serious adverse reactions, including pneumonitis, hepatitis, colitis, endocrinopathies, and other clinically important immune-related adverse events. Other warnings and precautions include infection, infusion-related reactions, and embryo-fetal toxicity.

Please see additional Important Safety Information on following page and in accompanying full Prescribing Information.
DISTRIBUTION AND FULFILLMENT INFORMATION

- TECENTRIQ is available through authorized specialty distributors and wholesalers via the TECENTRIQ distribution network.
- For additional network information, please contact Genentech BioOncology® Access Solutions by calling 1-888-249-4918 or by visiting www.genentech-access.com/tecentriq/hcp.

PATIENT ACCESS INFORMATION

- Genentech BioOncology Access Solutions offers a full range of access and reimbursement support for your patients and practice to minimize delays in therapy and understand patient coverage and out-of-pocket costs.
- For information on distribution and patient access support, please contact Genentech BioOncology Access Solutions for TECENTRIQ by calling 1-888-249-4918 or by visiting www.genentech-access.com/tecentriq/hcp.

For additional information, please contact your Genentech representative.

IMPORTANT SAFETY INFORMATION

**Serious Adverse Reactions**

Please refer to the full Prescribing Information for important dose management information specific to adverse reactions.

- **Immune-related pneumonitis**, including fatal cases. Permanently discontinue TECENTRIQ for grade 3 or 4 pneumonitis.
- **Immune-related hepatitis.** Immune-mediated hepatitis, including a fatal case, and liver test abnormalities have occurred. Permanently discontinue TECENTRIQ for grade 3 or 4 immune-mediated hepatitis.
- **Immune-related colitis**, including a fatal case of diarrhea-associated renal failure. Permanently discontinue TECENTRIQ for grade 4 diarrhea or colitis.
- **Immune-related endocrinopathies.** Immune-related thyroid disorders, adrenal insufficiency, hypophysitis, and type 1 diabetes mellitus, including diabetic ketoacidosis, have occurred. Permanently discontinue TECENTRIQ for grade 4 hypophysitis. For specific information on dose modifications, refer to Prescribing Information.
- **Other immune-related adverse reactions.** Meningoencephalitis, myasthenic syndrome/myasthenia gravis, Guillain-Barré syndrome, ocular inflammatory toxicity, and pancreatitis, including increases in serum amylase and lipase levels, have occurred. Permanently discontinue TECENTRIQ for any grade of meningitis or encephalitis; or myasthenic syndrome/myasthenia gravis or Guillain-Barré syndrome. Permanently discontinue TECENTRIQ for grade 4 or any grade of recurrent pancreatitis.
- **Infection.** Severe infections, including sepsis, herpes encephalitis, and mycobacterial infection leading to retroperitoneal hemorrhage have occurred.
- **Infusion-related reactions** have occurred. Permanently discontinue TECENTRIQ in patients with grade 3 or 4 infusion reactions.
- **Embryo-fetal toxicity.** TECENTRIQ can cause fetal harm in pregnant women. Advise females of reproductive potential to use effective contraception during treatment with TECENTRIQ and for at least 5 months after the last dose.
- **Advise female patients not to breastfeed while taking TECENTRIQ and for at least 5 months after the last dose.**

**Most Common Adverse Reactions**

The most common adverse reactions (rate ≥20%) included fatigue, decreased appetite, nausea, urinary tract infection, pyrexia, and constipation.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see accompanying full Prescribing Information for additional Important Safety Information.